Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: narita s. Int J Clin Oncol. 2024 Dec 17. doi: 10.1007/s10147-024-02681-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39688742
Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study.
Urabe F, Hatakeyama S, Yanagisawa T, Narita S, Muramoto K, Katsumi K, Takahashi H, Fukuokaya W, Mori K, Tashiro K, Iwatani K, Shimomura T, Miki J, Habuchi T, Kimura T; JHA Collaborative Group. Urabe F, et al. Among authors: narita s. Urol Oncol. 2024 Oct 9:S1078-1439(24)00670-7. doi: 10.1016/j.urolonc.2024.09.028. Online ahead of print. Urol Oncol. 2024. PMID: 39389903
Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.
Narita S, Yanagisawa T, Hatakeyama S, Hata K, Fujita K, Ueda T, Tanaka T, Maita S, Chiba S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Numakura K, Saito M, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Iwabuchi I, Suzuki T, Ukimura O, Kimura T, Ohyama C, Nomura K, Habuchi T. Narita S, et al. Prostate. 2025 Jan;85(1):73-81. doi: 10.1002/pros.24802. Epub 2024 Sep 30. Prostate. 2025. PMID: 39344365
546 results